You're tracking 0 roles at statsby.ai. Track a role to start building momentum here.
Company intel
From the job board · LinkedIn data via posting sync
Industry
Software Development
Company size
11 people
Headquarters
Pune
Founded
2022
Type
Privately Held
Statsby is a pharma-native AI and Data company. We work with pharma sponsors, biotechs, and clinical research organizations on the work that defines a trial — the protocols, statistical analysis plans, study reports, regulatory submissions, and the data that flows through them.
We're a team of problem solvers who believe the next generation of pharma breakthroughs will come from blending deep domain expertise with AI that's engineered for regulated environments — where auditability, traceability, and scientific rigor are the baseline.
That belief shows up in everything we ship.
Our platforms — Revectra and Veractra
Revectra is AI-powered protocol-to-platform intelligence. It turns clinical trial protocols — new and legacy — into structured, version-controlled CDISC USDM 4.0 study definitions, exposes them to downstream systems via API, and generates study documents with AI. Purpose-built for teams adopting Digital Data Flow.
Veractra is AI-powered Clinical Study Report generation that medical writers, reviewers, and regulatory teams can trust. ICH E3-compliant CSRs in days — every numerical claim verified against source TLFs, every sentence traceable to its origin, deployed entirely on your cloud.
Our Data & AI consulting
We partner with pharma sponsors, biotechs, and CROs to design and ship production-grade Data and AI systems — across data engineering, Generative AI, MLOps, and AI strategy — delivered by teams who understand clinical and scientific workflows as deeply as the technology that powers them.
If you're exploring our platforms, a consulting engagement, a partnership, or a place on the team, we'd be glad to connect.
→ statsby.ai
AI Strategy and Consulting
Data Engineering
Agentic AI
Generative AI
MLOps
Pharma AI
Clinical Research
Digital Data Flow
Clinical Study Reports
Protocol Digitization
CDISC USDM
and Clinical Development